All In Biotech

Drug Trial Radar · NCT07812116

A Study to Investigate Efficacy and Safety of Duvakitug in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-ranging Study to Evaluate the Efficacy and Safety of Duvakitug in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 156 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

156

Planned (sponsor's estimate)

Start

Oct 19, 2026

Primary completion

Jun 16, 2028

Study completion Nov 8, 2030

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
Collaborators
Teva Branded Pharmaceutical Products R&D LLC
First posted
Sep 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a parallel, Phase 2b, 3-arm, double-blind, randomized, multicenter, multinational, placebo-controlled, dose-ranging study to evaluate the efficacy and the safety of different doses of duvakitug in adult participants with moderate to severe hidradenitis suppurativa. Study details include: * The study duration will be up to 145 weeks , including a 4-week screening period, a 16-week initial double-blind treatment period, a 24-week active blinded extension period, a 96-week long-term extension period and a 5-week follow-up period. * The treatment duration will be up to 40 weeks for the participants who will stop after the active blinded extension period and up to 136 weeks for the participants who will continue in the long-term extension period. * The number of visits will be up to 23 for the participants who will stop after the active blinded extension period and up to 71 for the participants who will continue in the long-term extension period.

Conditions

  • Hidradenitis

Interventions

  • DuvakitugDrug

    Pharmaceutical form: Solution for injection Route of administration: Subcutaneous injection

  • PlaceboDrug

    Pharmaceutical form: Solution for injection Route of administration: Subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants achieving Hidradenitis Suppurativa Clinical Response 75 (HiSCR75)Time frame: At Week 16

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • Cahaba Dermatology & Skin Health Center- Site Number : 8400004

    Birmingham, Alabama · Recruiting

  • Florida International Research Center- Site Number : 8400002

    Miami, Florida · Recruiting

  • Investigational Site Number : 1240002

    Peterborough, Ontario, Canada · Recruiting

  • Investigational Site Number : 1240006

    Richmond Hill, Ontario, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.